Amino alkynylisoquinoline and alkynylnaphthyridine compounds potently inhibit acute myeloid leukemia proliferation in mice
Open Access
- 1 February 2019
- journal article
- research article
- Published by Elsevier in EBioMedicine
- Vol. 40, 231-239
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemiaNature, 2012
- Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitorsLeukemia, 2012
- FLT3 inhibitors: a story of the old and the newCurrent Opinion in Hematology, 2011
- mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3- mutated acute myeloid leukemia cellsMolecular Cancer, 2010
- Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile PharmacophoreJournal of Medicinal Chemistry, 2010
- MSK1 activation in acute myeloid leukemia cells with FLT3 mutationsLeukemia, 2010
- AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)Blood, 2009
- Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistanceBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2007
- Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemiaBlood, 2006
- Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutationsExperimental Hematology, 2005